FDA-Approved, Unique Algorithm Interprets ECG Signals for 16 Heart Rhythm Disorders
April 20, 2007 — Monebo Technologies Inc., Austin, TX, announced today that its Interpretive ECG Algorithm has been approved by the FDA and is commercially available now. The algorithm is used for the assessment of heart arrhythmias using ambulatory ECG data, and provides the most comprehensive arrhythmia analysis and interpretation available in a multiuse algorithm.
The algorithm will be integrated into individual ambulatory ECG monitoring devices where it will trigger the device to begin recording based on the identification of certain heart rhythms, and also will be used to interpret the ECG signal once it is transmitted to a centralized call center, providing a high level of accuracy while increasing the efficiency of the interpretation process. The technology will be licensed to medical device companies worldwide for incorporation into products that monitor cardiac electrical activity.
Based on Monebo's proprietary technology, the algorithm is designed to analyze the signal on a beat-by-beat basis, identify the key components of the ECG, and apply specific rules for the identification of cardiac arrhythmias. Because it is utilized in small, portable devices, it employs specialized processes that result in minimal processing time and resource requirements, while maximizing power management and battery life. The product features QRS and Ventricular Ectopic Beat detection, QRS feature extraction, interval measurement, heart rate measurement, and rhythm analysis for up to 16 leads of captured data.
More like this
- Algorithm Interprets ECG Signals for 16 Heart Rhythm Disorders
- ECG on a Chip Technology Available to Speed Device Development
- Monebo Remote, Wireless ECG Monitoring Belt Cleared in U.S.
- Vasomedical Introduces BIOX Holter Monitor, Analysis Software
- Breakthrough Algorithms Predict Sudden Cardiac Death Risk